Conditions: HCC
Interventions: Drug: VRT106; Drug: VRT106 in combination with camrelizumab and apatinib; Drug: Investigator’s Choice of Standard of Care
Sponsors: Guangzhou Virotech Pharmaceutical Co., Ltd.
Recruiting Conditions: HCC
Interventions: Drug: VRT106; Drug: VRT106 in combination with camrelizumab and apatinib; Drug: Investigator’s Choice of Standard of Care
Sponsors: Guangzhou Virotech Pharmaceutical Co., Ltd.
Recruiting
